Literature DB >> 30552544

Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.

Nicola Melillo1,2, Leon Aarons3, Paolo Magni4, Adam S Darwich3.   

Abstract

Regulatory agencies have a strong interest in sensitivity analysis for the evaluation of physiologically-based pharmacokinetic (PBPK) models used in pharmaceutical research and drug development and regulatory submissions. One of the applications of PBPK is the prediction of fraction absorbed and bioavailability for drugs following oral administration. In this context, we performed a variance based global sensitivity analysis (GSA) on in-house PBPK models for drug absorption, with the aim of identifying key parameters that influence the predictions of the fraction absorbed and the bioavailability for neutral, acidic and basic compounds. This analysis was done for four different classes of drugs, defined according to the Biopharmaceutics Classification System, differentiating compounds by permeability and solubility. For class I compounds (highly permeable, highly soluble), the parameters that mainly influence the fraction absorbed are related to the formulation properties, for class II compounds (highly permeable, lowly soluble) to the dissolution process, for class III (lowly permeable, highly soluble) to both absorption process and formulation properties and for class IV (lowly permeable, lowly soluble) to both absorption and dissolution processes. Considering the bioavailability, the results are similar to those for the fraction absorbed, with the addition that parameters related to gut wall and liver clearance influence as well the predictions. This work aimed to give a demonstration of the GSA methodology and highlight its importance in improving our understanding of PBPK absorption models and in guiding the choice of parameters that can safely be assumed, estimated or require data generation to allow informed model prediction.

Keywords:  BCS; Drug absorption; Global sensitivity analysis; Oral bioavailability; PBPK; Variance based GSA

Mesh:

Substances:

Year:  2018        PMID: 30552544     DOI: 10.1007/s10928-018-9615-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  30 in total

1.  A compartmental absorption and transit model for estimating oral drug absorption.

Authors:  L X Yu; G L Amidon
Journal:  Int J Pharm       Date:  1999-09-20       Impact factor: 5.875

Review 2.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

Authors:  B Agoram; W S Woltosz; M B Bolger
Journal:  Adv Drug Deliv Rev       Date:  2001-10-01       Impact factor: 15.470

3.  Applications of physiologically based absorption models in drug discovery and development.

Authors:  Neil Parrott; Thierry Lave
Journal:  Mol Pharm       Date:  2008-06-12       Impact factor: 4.939

Review 4.  Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.

Authors:  Arik Dahan; Jonathan M Miller; Gordon L Amidon
Journal:  AAPS J       Date:  2009-10-30       Impact factor: 4.009

5.  A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models.

Authors:  Megerle L Scherholz; James Forder; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-08       Impact factor: 2.745

Review 6.  Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.

Authors:  H Lennernäs; L Aarons; P Augustijns; S Beato; M Bolger; K Box; M Brewster; J Butler; J Dressman; R Holm; K Julia Frank; R Kendall; P Langguth; J Sydor; A Lindahl; M McAllister; U Muenster; A Müllertz; K Ojala; X Pepin; C Reppas; A Rostami-Hodjegan; M Verwei; W Weitschies; C Wilson; C Karlsson; B Abrahamsson
Journal:  Eur J Pharm Sci       Date:  2013-11-01       Impact factor: 4.384

7.  IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

Authors:  Alison Margolskee; Adam S Darwich; Xavier Pepin; Leon Aarons; Aleksandra Galetin; Amin Rostami-Hodjegan; Sara Carlert; Maria Hammarberg; Constanze Hilgendorf; Pernilla Johansson; Eva Karlsson; Dónal Murphy; Christer Tannergren; Helena Thörn; Mohammed Yasin; Florent Mazuir; Olivier Nicolas; Sergej Ramusovic; Christine Xu; Shriram M Pathak; Timo Korjamo; Johanna Laru; Jussi Malkki; Sari Pappinen; Johanna Tuunainen; Jennifer Dressman; Simone Hansmann; Edmund Kostewicz; Handan He; Tycho Heimbach; Fan Wu; Carolin Hoft; Loic Laplanche; Yan Pang; Michael B Bolger; Eva Huehn; Viera Lukacova; James M Mullin; Ke X Szeto; Chester Costales; Jian Lin; Mark McAllister; Sweta Modi; Charles Rotter; Manthena Varma; Mei Wong; Amitava Mitra; Jan Bevernage; Jeike Biewenga; Achiel Van Peer; Richard Lloyd; Carole Shardlow; Peter Langguth; Irina Mishenzon; Mai Anh Nguyen; Jonathan Brown; Hans Lennernäs; Bertil Abrahamsson
Journal:  Eur J Pharm Sci       Date:  2016-11-02       Impact factor: 4.384

8.  IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

Authors:  Adam S Darwich; Alison Margolskee; Xavier Pepin; Leon Aarons; Aleksandra Galetin; Amin Rostami-Hodjegan; Sara Carlert; Maria Hammarberg; Constanze Hilgendorf; Pernilla Johansson; Eva Karlsson; Dónal Murphy; Christer Tannergren; Helena Thörn; Mohammed Yasin; Florent Mazuir; Olivier Nicolas; Sergej Ramusovic; Christine Xu; Shriram M Pathak; Timo Korjamo; Johanna Laru; Jussi Malkki; Sari Pappinen; Johanna Tuunainen; Jennifer Dressman; Simone Hansmann; Edmund Kostewicz; Handan He; Tycho Heimbach; Fan Wu; Carolin Hoft; Yan Pang; Michael B Bolger; Eva Huehn; Viera Lukacova; James M Mullin; Ke X Szeto; Chester Costales; Jian Lin; Mark McAllister; Sweta Modi; Charles Rotter; Manthena Varma; Mei Wong; Amitava Mitra; Jan Bevernage; Jeike Biewenga; Achiel Van Peer; Richard Lloyd; Carole Shardlow; Peter Langguth; Irina Mishenzon; Mai Anh Nguyen; Jonathan Brown; Hans Lennernäs; Bertil Abrahamsson
Journal:  Eur J Pharm Sci       Date:  2016-09-28       Impact factor: 4.384

9.  Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.

Authors:  Andrés Olivares-Morales; Avijit Ghosh; Leon Aarons; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-09-08       Impact factor: 4.009

10.  Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models.

Authors:  X-Y Zhang; M N Trame; L J Lesko; S Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-02
View more
  7 in total

1.  A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms.

Authors:  Nan-Hung Hsieh; Frédéric Y Bois; Eleftheria Tsakalozou; Zhanglin Ni; Miyoung Yoon; Wanjie Sun; Martin Klein; Brad Reisfeld; Weihsueh A Chiu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-22       Impact factor: 2.410

2.  Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series.

Authors:  Mark McAllister; Talia Flanagan; Susan Cole; Andreas Abend; Evangelos Kotzagiorgis; Jobst Limberg; Heather Mead; Victor Mangas-Sanjuan; Paul A Dickinson; Andrea Moir; Xavier Pepin; Diansong Zhou; Christophe Tistaert; Aristides Dokoumetzidis; Om Anand; Maxime Le Merdy; David B Turner; Brendan T Griffin; Adam Darwich; Jennifer Dressman; Claire Mackie
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

3.  Well-tempered MCMC simulations for population pharmacokinetic models.

Authors:  Frederic Y Bois; Nan-Hung Hsieh; Wang Gao; Weihsueh A Chiu; Brad Reisfeld
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-07-31       Impact factor: 2.745

4.  Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.

Authors:  Doha Naga; Neil Parrott; Gerhard F Ecker; Andrés Olivares-Morales
Journal:  Mol Pharm       Date:  2022-04-27       Impact factor: 5.364

5.  Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models.

Authors:  Dan Liu; Linzhong Li; Amin Rostami-Hodjegan; Frederic Y Bois; Masoud Jamei
Journal:  AAPS J       Date:  2020-07-17       Impact factor: 4.009

6.  Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds.

Authors:  Nicola Melillo; Silvia Grandoni; Nicola Cesari; Giandomenico Brogin; Paola Puccini; Paolo Magni
Journal:  AAPS J       Date:  2020-08-30       Impact factor: 4.009

7.  A latent variable approach to account for correlated inputs in global sensitivity analysis.

Authors:  Nicola Melillo; Adam S Darwich
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-25       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.